^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aphexda (motixafortide)

    i
    Other names: BL-8040, BKT140 SC, TN-14003, BKT 140, BL 8040, TF-14016, 4F-benzoyl-TN14003, BKT-140
    Associations

    News

    Trials
    Company:
    Ayrmid, BioLineRx, GenFleet Therap, Gloria Pharma
    Drug class:
    CXCR4 antagonist
    Related drugs:
    Associations

    News

    Trials
    10d
    WBC Growth Factors: ASCO Guideline Update. (PubMed, J Clin Oncol)
    Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics. For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide. The guideline also provides information about the dosing and selection of CSFs.Additional information is available at www.asco.org/supportive-care-guidelines.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Aphexda (motixafortide) • plerixafor
    24d
    Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
    P4, N=94, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Hemady (dexamethasone tablets) • Aphexda (motixafortide)
    28d
    Motixafortide for MRD Sensitization in AML (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    Aphexda (motixafortide)
    3ms
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients (clinicaltrials.gov)
    P3, N=60, Recruiting, Guangzhou Gloria Biosciences Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Aphexda (motixafortide)
    3ms
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    3ms
    A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging. (PubMed, Sci Rep)
    A proof-of-principle drug screen identified PF 573228 (FAK inhibitor) and motixafortide (CXCR4 inhibitor) as potent suppressors of GBM20 and GBM1 infiltration, respectively. Bulk RNA sequencing revealed gene expression profiles correlating with invasive behaviour and drug sensitivity. This platform offers a valuable model for studying glioblastoma infiltration along axons and provides proof-of-principle that migration can serve as a measurable and actionable phenotype to screen therapeutic vulnerabilities in glioblastoma.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Aphexda (motixafortide) • PF-573228
    3ms
    Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
    P4, N=94, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hemady (dexamethasone tablets) • Aphexda (motixafortide)
    6ms
    SCD Stem Cell Mobilization and Apheresis Using Motixafortide (clinicaltrials.gov)
    P1, N=15, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Aphexda (motixafortide)
    6ms
    A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
    P1, N=20, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    Aphexda (motixafortide)
    7ms
    Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
    P4, N=94, Not yet recruiting, Emory University
    New P4 trial
    |
    Hemady (dexamethasone tablets) • Aphexda (motixafortide)
    7ms
    A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Aphexda (motixafortide)
    8ms
    Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
    P1, N=10, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    Aphexda (motixafortide) • Tysabri (natalizumab)